Elicio Therapeutics, Inc.
ELTX
$10.60
-$0.43-3.90%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 4.29% | 6.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.01% | -20.33% | |||
| Operating Income | 6.01% | 20.33% | |||
| Income Before Tax | 5.78% | 19.96% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 5.78% | 19.96% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 5.78% | 19.96% | |||
| EBIT | 6.01% | 20.33% | |||
| EBITDA | 6.04% | 20.22% | |||
| EPS Basic | 24.02% | 15.64% | |||
| Normalized Basic EPS | 21.04% | 15.63% | |||
| EPS Diluted | 24.02% | 15.64% | |||
| Normalized Diluted EPS | 21.04% | 15.63% | |||
| Average Basic Shares Outstanding | 24.01% | -5.13% | |||
| Average Diluted Shares Outstanding | 24.01% | -5.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||